For example, peptide ligands restricted to HLA-A*02:01 and A*24:02 that contain D/E in peptide position 4 could be of particular interest as targets for vaccines or T cell-based immunotherapies against viral diseases or cancer, especially for peptides with subdominant primary anchors. This evidence concerns the gene HLA-A and cancer.